ArticleFrontiers in bioengineering and biotechnology2026
Dissecting the disconnect between circuit activation and dominant adaptive evolution in cytoplasmic phage-assisted continuous evolution (PACE) of an EGFR nanobody.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cytoplasmic phage-assisted continuous evolution (PACE) is widely used due to its low selection pressure and straightforward circuit design. However, the reducing environment limits its applicability to mammalian proteins that rely on disulfide bonds or glycosylation. Methods: To evaluate whether these biochemical constraints inherently hinder cytoplasmic evolution, we confined both the antibody and the target protein to single-domain formats. We examined circuit activation and evolution of a 7D12 nanobody targeting the epidermal growth factor receptor domain III (EGFR DIII). Results: Nanobodies and EGFR DIII expressed in the cytoplasm retained their soluble fractions and pairing activity. These enabled efficient activation of the two-hybrid circuit and robust phage propagation. Despite successful circuit activation, neither non-continuous flow (PANCE) nor PACE generated affinity-enhanced variants under extended drift conditions and graded selection pressures designed to increase mutational diversity. Discussion: Although optimal PACE operating conditions inhibited cheater gene recombination and enabled sustained POI mutagenesis, mutational convergence may be more sensitive to organismal incompatibility than circuit activation. This aligns with the observed decoupling between circuit activation and productive adaptive evolution. Moreover, structural analysis and predicted saturation mutagenesis at the binding interface are consistent with interface accessibility as a plausible constraint. The 7D12 nanobody contains a narrow, protruding CDR3, and most substitutions at the CDR1 -CDR3 interface are neutral or deleterious. Although single-domain mammalian proteins can overcome organismal incompatibility for cytoplasmic PACE circuit activation, their evolvability may be influenced by limitations in the accessibility of beneficial mutations within the binding interface and by their combination with organism-level factors. These results support a multifactorial basis for evolvability in cytoplasmic PACE, involving both interface accessibility and system-level factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.